Yaniv Lustig

7.5k total citations · 3 hit papers
133 papers, 3.8k citations indexed

About

Yaniv Lustig is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Epidemiology. According to data from OpenAlex, Yaniv Lustig has authored 133 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Infectious Diseases, 44 papers in Public Health, Environmental and Occupational Health and 25 papers in Epidemiology. Recurrent topics in Yaniv Lustig's work include SARS-CoV-2 and COVID-19 Research (62 papers), Mosquito-borne diseases and control (42 papers) and Viral Infections and Vectors (38 papers). Yaniv Lustig is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (62 papers), Mosquito-borne diseases and control (42 papers) and Viral Infections and Vectors (38 papers). Yaniv Lustig collaborates with scholars based in Israel, United States and France. Yaniv Lustig's co-authors include Gili Regev‐Yochay, Victoria Indenbaum, Michal Mandelboim, Carmit Cohen, Marc Lipsitch, Yitshak Kreiss, Sharon Amit, Ella Mendelson, Carmit Rubin and Neta S. Zuckerman and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Nature Communications.

In The Last Decade

Yaniv Lustig

123 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

2021 814 citations Tal Gonen, Yaniv Lustig et al. profile →
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

2021 232 citations Yaniv Lustig, Gili Regev‐Yochay et al. profile →
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

2021 194 citations Gili Regev‐Yochay, Yaniv Lustig et al. profile →

Peers

Countries citing papers authored by Yaniv Lustig

Since Specialization

Citations

This map shows the geographic impact of Yaniv Lustig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaniv Lustig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaniv Lustig more than expected).

Fields of papers citing papers by Yaniv Lustig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaniv Lustig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaniv Lustig. The network helps show where Yaniv Lustig may publish in the future.

Co-authorship network of co-authors of Yaniv Lustig

This figure shows the co-authorship network connecting the top 25 collaborators of Yaniv Lustig. A scholar is included among the top collaborators of Yaniv Lustig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaniv Lustig. Yaniv Lustig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transfusion-transmitted infections: risks and mitigation strategies for Oropouche virus and other emerging arboviruses in Latin America and the Caribbean 2025 ·The Lancet Regional Health - Americas ·Andrés Moreira‐Soto, (unknown), (unknown), (unknown), Carlo Fischer, Eduardo Gotuzzo, Thomas Jaenisch, José Eduardo Levi, Yaniv Lustig, Jan Felix Drexler	1
2	Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study (ICoFS) 2025 ·The Journal of Infectious Diseases ·(unknown), Mayan Gilboa, Maylis Layan, Gili Joseph, (unknown), Sharon Amit, Carmit Rubin, Yaniv Lustig, Sharon Alroy‐Preis, Yitshak Kreiss, Simon Cauchemez, Gili Regev‐Yochay	0
3	Incursion of SARS-CoV-2 BA.2.86.1 variant into Israel: National-scale wastewater surveillance using a novel quantitative real-time PCR assay 2024 ·The Science of The Total Environment ·Oran Erster, Itay Bar-Or, Roberto Azar, (unknown), (unknown), Batya Mannasse, (unknown), (unknown), (unknown), Ruth Yishai, (unknown), (unknown), (unknown), (unknown), Michal Mandelboim, Neta S. Zuckerman, Danit Sofer, Yaniv Lustig	0
4	Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers 2024 ·Vaccine ·(unknown), Noam Barda, Yaniv Lustig, (unknown), Victoria Indenbaum, (unknown), Neta S. Zuckerman, Keren Asraf, Sharon Amit, Yitshak Kreiss, Gili Regev‐Yochay	4
5	Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines 2024 ·Vaccine ·Yaniv Lustig, Noam Barda, (unknown), Victoria Indenbaum, Ili Margalit, Keren Asraf, Ram Doolman, Spyros Chalkias, Rituparna Das, (unknown), (unknown), Yitshak Kreiss, Gili Regev‐Yochay	2
6	Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study 2024 ·Viruses ·Gili Joseph, Ili Margalit, (unknown), Carmit Rubin, Havi Murad, Raquel C. Gardner, Noam Barda, (unknown), Victoria Indenbaum, Mayan Gilboa, Sharon Alroy‐Preis, Yitshak Kreiss, Yaniv Lustig, Gili Regev‐Yochay	4
7	SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023 2024 ·Emerging infectious diseases ·Yaniv Lustig, (unknown), Victoria Indenbaum, (unknown), (unknown), Ili Margalit, Keren Asraf, (unknown), Neta S. Zuckerman, (unknown), Michal Mandelboim, Ram Doolman, Noam Barda, Gili Regev‐Yochay	2
8	Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients 2023 ·Viruses ·Yana Davidov, Victoria Indenbaum, Michal Mandelboim, Keren Asraf, Tal Gonen, (unknown), Oranit Cohen‐Ezra, Mariya Likhter, Ital Nemet, Limor Kliker, Orna Mor, Ram Doolman, Carmit Cohen, Arnon Afek, Yitshak Kreiss, Gili Regev‐Yochay, Yaniv Lustig, Ziv Ben‐Ari	1
9	The Role of NS1 Protein in the Diagnosis of Flavivirus Infections 2023 ·Viruses ·(unknown), Yaniv Lustig, Ella H. Sklan, Eli Schwartz	26
10	Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders 2023 ·PLoS ONE ·Hila Magen, Abraham Avigdor, (unknown), Shalev Fried, (unknown), E G Levin, Yaniv Lustig, (unknown), Galia Rahav	1
11	A case report of human infection with lymphocytic choriomeningitis virus in Israel 2022 ·Journal of Medical Virology ·(unknown), Yaniv Lustig, Tal Brosh‐Nissimov	1
12	Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study 2022 ·Vaccine ·Shirley Shapiro Ben David, Barak Mizrahi, (unknown), Lia Supino‐Rosin, (unknown), (unknown), (unknown), (unknown), (unknown), Nir Kalkstein, Yaniv Lustig, Victoria Indenbaum, (unknown), (unknown), (unknown)	4
13	The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection 2022 ·Clinical Infectious Diseases ·Noam Barda, (unknown), Mayan Gilboa, Keren Asraf, (unknown), (unknown), Sharon Amit, (unknown), Ram Doolman, Ella Mendelson, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev‐Yochay	12
14	Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up 2022 ·Nature Communications ·(unknown), Noam Barda, Mayan Gilboa, Victoria Indenbaum, Michal Mandelboim, Tal Gonen, Keren Asraf, (unknown), Sharon Amit, Ram Doolman, Ella Mendelson, (unknown), Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev‐Yochay	16
15	Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022 2022 ·Eurosurveillance ·Noam Barda, (unknown), Mayan Gilboa, (unknown), Keren Asraf, (unknown), Sharon Amit, (unknown), Ram Doolman, Ella Mendelson, (unknown), Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev‐Yochay	5
16	Can Biomarkers of Oxidative Stress in Serum Predict Disease Severity in West Nile Virus Infection? A Pilot Study 2022 ·Tropical Medicine and Infectious Disease ·(unknown), Annelies Breynaert, Tess De Bruyne, Corneliu Petru Popescu, Simin Aysel Florescu, Yaniv Lustig, Eli Schwartz, Federico Gobbi, Nina Hermans, Ralph Huits	1
17	Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study 2021 ·Eurosurveillance ·Yaniv Lustig, Carmit Cohen, Asaf Biber, Hanaa Jaber, (unknown), Victoria Indenbaum, Sharon Amit, Michal Mandelboim, Ella Mendelson, Gili Regev‐Yochay	0
18	Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy 2021 ·American Journal of Obstetrics & Gynecology MFM ·(unknown), A. Schwartz, Shlomi Toussia‐Cohen, Leah Leibovitch, Tzipora Strauss, Keren Asraf, Ram Doolman, (unknown), Carmit Cohen, Yaniv Lustig, Gili Regev‐Yochay, Yoav Yinon	69
19	Interleukin-1α deficiency reduces adiposity, glucose intolerance and hepatic de-novo lipogenesis in diet-induced obese mice 2019 ·BMJ Open Diabetes Research & Care ·Tal Almog, (unknown), (unknown), Gadi Shlomai, Iris Barshack, Rinke Stienstra, Yaniv Lustig, (unknown), Ayelet Harari, Yoram Bujanover, (unknown), Aviv Shaish, Dror Harats, Yehuda Kamari	20
20	Spliced‐leader RNA silencing: a novel stress‐induced mechanism in Trypanosoma brucei 2007 ·EMBO Reports ·Yaniv Lustig, Lilach Sheiner, Yaron Vagima, Hanoch Goldshmidt, Anish Das, Vivian Bellofatto, Shulamit Michaeli	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact